• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 3. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 4. An ion-gating multinanochannel system based on a copper-responsive self-cleaving DNAzyme?
  Yang Chen,Di Zhou,Zheyi Meng,Jin Zhai Chem. Commun., 2016,52, 10020-10023
• 5. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392

Recent Advances in the Study of 3-Ethoxy-4-hydroxyphenylacetic Acid (CAS: 8007-18-9)

3-Ethoxy-4-hydroxyphenylacetic acid (CAS: 8007-18-9) is a phenolic acid derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. Recent studies have explored its role as an intermediate in the synthesis of bioactive compounds, its antioxidant properties, and its potential use in treating inflammatory and metabolic disorders. This research brief aims to summarize the latest findings related to this compound, highlighting its chemical properties, biological activities, and potential applications in drug development.

One of the key areas of research has been the synthesis and optimization of 3-Ethoxy-4-hydroxyphenylacetic acid. A study published in the Journal of Medicinal Chemistry (2023) demonstrated an improved synthetic route for this compound, achieving higher yields and purity. The researchers utilized a green chemistry approach, reducing the use of hazardous solvents and improving the overall sustainability of the process. This advancement is particularly relevant for scaling up production for pharmaceutical applications.

In terms of biological activity, recent in vitro and in vivo studies have shed light on the compound's antioxidant and anti-inflammatory effects. A 2024 study in the European Journal of Pharmacology reported that 3-Ethoxy-4-hydroxyphenylacetic acid significantly reduced oxidative stress markers in a rodent model of diabetes. The compound was found to scavenge free radicals and upregulate endogenous antioxidant enzymes, suggesting its potential as a therapeutic agent for oxidative stress-related diseases.

Another promising area of research involves the compound's role in metabolic regulation. A preprint from BioRxiv (2024) highlighted its ability to modulate glucose metabolism in adipocytes, indicating potential applications in managing metabolic syndrome and type 2 diabetes. The study identified specific molecular targets, including PPAR-γ and AMPK pathways, which are critical in energy homeostasis.

Despite these promising findings, challenges remain in the clinical translation of 3-Ethoxy-4-hydroxyphenylacetic acid. Pharmacokinetic studies are still limited, and further research is needed to optimize its bioavailability and tissue distribution. Additionally, comprehensive toxicological assessments are required to ensure its safety profile for human use. Future studies should focus on these aspects to bridge the gap between preclinical findings and clinical applications.

In conclusion, 3-Ethoxy-4-hydroxyphenylacetic acid (CAS: 8007-18-9) represents a compound of significant interest in chemical biology and pharmaceutical research. Its diverse biological activities, coupled with recent advancements in synthesis and mechanistic understanding, position it as a promising candidate for further drug development. Continued research efforts will be essential to fully realize its therapeutic potential and address existing challenges in its clinical application.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)